Navigation Links
Cempra, Inc., Announces Notification of Patent Allowance for U.S. Patent Application on Taksta Loading Dose Formulation
Date:5/30/2013

CHAPEL HILL, N.C., May 30, 2013 /PRNewswire/ -- Cempra, Inc., (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,450,300 on May 28, 2013 with claims directed to the company's novel loading dose regimen for Taksta™.  The patent, entitled "Fusidic Acid Dosing Regimens for Treatment of Bacterial Infections," provides protection until 2029, excluding possible patent term extensions. 

"The issuance of this patent may add to the commercial value of Taksta as an important antibiotic candidate, currently in a Phase 2 clinical study in patients with prosthetic joint infections," said Prabhavathi Fernandes , Ph.D., chief executive officer of Cempra.  "Our now proprietary loading dose regimen for Taksta was a novel innovation designed so that the drug would rapidly reach therapeutic blood levels and minimize the risk of drug resistance. The patent provides protection in addition to the expected U.S. market exclusivity obtained through Waxman-Hatch, the GAIN Act, pediatric testing and, possibly, the Orphan Drug Act."

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases.  Cempra's two lead product candidates are currently in advanced clinical development.  Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan.  Taksta™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections.  Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the results of studies of our product candidates conducted by others; the results, timing, costs and regulatory review of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; and innovation by our competitors. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

Investor and Media Contacts:
Robert E. Flamm , Ph.D.
Russo Partners, LLC
(212) 845-4226 
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com


'/>"/>
SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
2. Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
3. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
4. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
5. Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
6. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
7. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
8. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
9. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
10. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
11. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... to and which He does not. Yisrayl says with so many titles and names ... name, but he says with a little Scripture, backed with a lot of research, the ...
(Date:4/28/2017)... ... 28, 2017 , ... Intellitec Solutions announced the publication of ... Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software package. With ... care, Brooke Grove now has the capability to achieve its goal for a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
Breaking Medicine News(10 mins):